1-2 February, 2023  |  Online Conference
This virtual conference was jointly organised by BSAC and GARDP. This conference is CPD accredited.
Abstract submission
For ACC2023, the collaborating organisations were Africa CDC and ReAct Africa.

Programme

Recorded content from this conference can be viewed below.

SESSION ONE: KEYNOTE PRESENTATION

View session one. This video consists of the following presentations:

Watch Presentation

Introductory remarks

Professor Laura JV Piddock, Scientific Director, GARDP - View Bio

Is antimicrobial discovery responding to current needs? How do we move from here?

Dr Mirfin Mpundu, Director, ReAct Africa - View Bio

Q&A

SESSION TWO: Drug discovery - new targets and new chemistry

View session two. This video consists of the following presentations:

Watch Presentation

Antiviral drug discovery: preparing for the next pandemic

Professor Rosemary Dorrington, Professor: Marine natural Products Research, Rhodes University - View Bio

Awakening sleeping antibiotics

Professor Gilles P. van Wezel, Director, Institute of Biology & Professor of Microbial Biotechnology, Leiden University, The Netherlands - View Bio

Bioinformatics as a tool to identify and synthesise of new antibiotics

Dr César de la Fuente, Presidential Assistant Professor, University of Pennsylvania - View Bio

Q&A

SESSION THREE: Preclinical antimicrobial development

View session three. This video consists of the following presentations:

Watch Presentation

Recent developments in PK-PD

Professor Lena Friberg, Professor of Pharmacokinetics and Pharmacodynamics at the Department of Pharmacy, Uppsala University, Sweden - View Bio

Challenges of discovery of new antibiotics

Dr Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna - View Bio

Discovery and pre-clinical development of new antimicrobials in Africa

Dr Greg Basarab, H3D - University of Cape Town - View Bio

Q&A

SESSION FOUR: Panel discussion - Development of non-traditional antimicrobials

View session four. This video consists of the following presentations:

Watch Presentation

Panellist

Dr Peter Jackson, Executive Director, INFEX Therapeutics Ltd - View Bio

Panellist

Dr Richard Alm, Chief Scientist, CARB-X - View Bio

Panellist

Dr Nagasuma Chandra, PhD Professor Department of Biochemistry Indian Institute of Science, Bangalore, India - View Bio

Day One - Closing remarks

Dr Christopher Longshaw, Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer - View Bio

SESSION FIVE: Clinical Development and Use of New agents

View session five. This video consists of the following presentations:

Watch Presentation

Introductory remarks

Dr Christopher Longshaw, Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer - View Bio

Zoliflodacin Phase 3 study

Professor Sinead Delany-Moretlwe, Director: Research, Wits RHI & Professor of Global Health & Infectious Diseases, University of the Witwatersrand, Johannesburg - View Bio

Clinical trials in countries with a high burden of drug resistance

Dr Ashima Bhatia, MD – Chief Clinical Officer & Head, Global Clinical Development, Wockhardt - View Bio

Compassionate use of Cefiderocol to treat documented XDR-AB infections at the intensive care unit

Professor Federico Pea, Full Professor of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy - View Bio

Q&A

SESSION SIX: ORAL POSTER PRESENTATIONS

View session six. This video consists of the following presentations:

Watch Presentation

Association of meropenem with ethambutol enhances the exposure of Mycobacterium tuberculosis peptidoglycan and promotes its synergistic killing

Mr Francisco Olivença, PhD Candidate, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal - View Bio

Assessment of availability of essential antimicrobial agents in north India

Dr Rachna Rohilla, Assistant Professor, Department of Pharmacology, AIIMS Bathinda - View Bio

The SA-UK Antimicrobial Drug Discovery Hub: Harnessing the potential of natural products as antimicrobial lead compounds

Miss Roxanne Leigh Higgitt, Department of Biochemistry and Microbiology, Rhodes University, Makhanda, South Africa - View Bio

Interplay Between Clinical Stringent Response-Activating Mutations, Antibiotic Tolerance and Bacterial Fitness

Dr Joanne Hobbs, Research Associate & Adjunct Assistant Professor, Department of Biochemistry & Microbiology, University of Victoria, Canada - View Bio

Infection control of Healthcare-associated infections in Ukraine

Dr Yulian Konechnyi, National Medical University, Lviv, Ukraine - View Bio

Q&A

SESSION SEVEN: National action plan progress/policy

View session seven. This video consists of the following presentations:

Watch Presentation

Development of the National Policy and Action Plan and accompanying strategies for Antimicrobial Resistance in Kenya

Dr Evelyn Wesangula, Senior AMR Control Specialist, East Central and Southern Africa Health Community (ECSA- HC) - View Bio

MAAP DATA

Dr Pascale Ondoa, Director of Science & New Initiatives, African Society for Laboratory Medicine (ASLM) - View Bio

Widening access to antibiotics in LMICs

Professor Samuel Kariuki, Chief Research Scientist and Director, Research and Development, Kenya Medical Research Institute (KEMRI), Kenya - View Bio

Q&A

SESSION EIGHT: Panel discussion - Regulatory paths for new treatment modalities

View session eight. This video consists of the following presentations:

Watch Presentation

Panellist

Dr Markus Zeitlinger, University of Vienna - View Bio

Panellist

Dr Mimi Yen, Phage Pro - View Bio

Panellist

Dr Joe Campbell, National Institute of Allergies and Infectious Diseases (NIAID) - View Bio

Closing remarks

Professor Laura JV Piddock, Scientific Director, GARDP - View Bio

Virtual poster gallery

Click here to view the virtual poster gallery from the conference